De‐Escalation of Disease‐Modifying Therapy in Multiple Sclerosis—A Danish Nationwide Cohort Study
European Journal of Neurology · 2025
DOI: 10.1111/ene.70042 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Frederik Elberling und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Danish Multiple Sclerosis Registry, Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, G…. Hauptthemen laut MEDLINE: Multiple Sclerosis, Relapsing-Remitting, Natalizumab, Fingolimod Hydrochloride, Immunologic Factors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objective High‐efficacy (HE) disease‐modifying therapies (DMT) are increasingly used to treat multiple sclerosis (MS). Concerns arise when considering the decreasing efficacy and increasing risk of adverse events in aging patients. We aimed to describe disease activity and treatment trajectories in patients with MS who de‐escalated from an HE DMT to an moderate‐efficacy (ME) DMT.
Methods
We performed a cohort study based on data from the Danish Multiple Sclerosis Registry (DMSR) including patients with relapsing–remitting MS (RRMS), who switched from an HE DMT to an ME DMT as defined by Danish authorities. We included patients from October 2007 to July 2023. Median follow‐up time was 0.8 years (IQR 0.3–2.5).
Results
In total 333 patients (76.0% females, mean age: 45.1 years) de‐escalated for various reasons. Most patients de‐escalated from natalizumab or fingolimod (43.8% and 42.0%, respectively) to dimethyl fumarate (47.5%). At 2 years after de‐escalation, the cumulative risk of relapse was 38% (95% CI 31–44) and 53% (95% CI 46–60) for inflammatory disease activity (relapses and/or radiological disease activity). Age (HR 0.96, 95% CI 0.94–0.98) and inflammatory disease activity prior to de‐escalation (HR 2.05, 95% CI 1.45–2.91) were associated with inflammatory disease activity post de‐escalation.
Discussion
De‐escalation from primarily natalizumab and fingolimod did not effectively ensure disease stability in this cohort. Younger age and inflammatory disease activity prior to de‐escalation were risk factors for inflammatory disease activity post de‐escalation, which can help guide future studies on de‐escalation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Danish Multiple Sclerosis Registry, Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Mie Reith Mahler, Luigi Pontieri, Melinda Magyari
Zitieren
APA
Elberling, F., Mahler, M. R., Pontieri, L., Sellebjerg, F., Magyari, M., & DMSG Study Group (2025). De‐Escalation of Disease‐Modifying Therapy in Multiple Sclerosis—A Danish Nationwide Cohort Study. European Journal of Neurology. https://doi.org/10.1111/ene.70042
Vancouver
Elberling F, Mahler MR, Pontieri L, Sellebjerg F, Magyari M, DMSG Study Group. De‐Escalation of Disease‐Modifying Therapy in Multiple Sclerosis—A Danish Nationwide Cohort Study. European Journal of Neurology. 2025. doi:10.1111/ene.70042
BibTeX
@article{Elberling2025,
author = {Elberling, Frederik and Mahler, Mie Reith and Pontieri, Luigi and Sellebjerg, Finn and Magyari, Melinda and DMSG Study Group, DMSG Study Group},
title = {De‐Escalation of Disease‐Modifying Therapy in Multiple Sclerosis—A Danish Nationwide Cohort Study},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.70042}
}
EUVIMED